{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T18:39:45Z","timestamp":1793990385601,"version":"4.8.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>With the introduction of the latest class of biologic drugs targeting interleukin (IL)-23p19, three new, highly effective drugs can be used for the treatment of chronic plaque psoriasis. However, poorer skin improvement as well as higher rates of serious adverse events have been reported for patients under real-world conditions (outside clinical trials). This accounts especially for patients who have already been treated with biologic drugs. We therefore aimed to determine effectiveness and safety of IL-23p19 inhibitors in real-world patients by analysing data from the Psoriasis Registry Austria (PsoRA) in this observational, retrospective, multicentre cohort study. Data for 197 patients (52.3% biologic-non-na\u00efve), who were treated with anti-IL-23p19 antibodies (127 guselkumab, 55 risankizumab and 15 tildrakizumab) for at least 3\u00a0months, were eligible for analysis. In general, biologic-non-na\u00efve patients displayed a less favourable response to anti-IL-23 treatment as compared to biologic-na\u00efve patients. However, after correction for previous biologic exposure, few differences in PASI improvement were detected among biologic-na\u00efve and -non-na\u00efve patients treated with different IL-23p19 inhibitors. This indicates that treatment effectiveness is not related to the class of the previously administered therapy in biologic-non-na\u00efve patients. Therefore, IL-23p19 inhibitors represent a promising treatment alternative for patients who have not responded to previous biologics. However, as with other biologic agents (including IL-17 inhibitors), we did not observe an entirely satisfactory treatment response\u00a0(i.e. PASI &lt; 3 and\/or PASI 75) to anti-IL-23 treatment in one out of four to five patients. Adverse events (mainly non-severe infections) were observed in 23 (11.7%) patients with no major differences regarding the administered IL-23 inhibitor or previous biologic exposure.<\/jats:p>","DOI":"10.1038\/s41598-022-18790-9","type":"journal-article","created":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T08:10:55Z","timestamp":1662365455000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA)"],"prefix":"10.1038","volume":"12","author":[{"given":"T.","family":"Graier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Weger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Jonak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Sator","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Zikeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Prillinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Sassmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Gruber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Saxinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Ratzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Painsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mlynek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"H\u00e4ring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Sadoghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Trattner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"M\u00fcllegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Quehenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Salmhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,5]]},"reference":[{"key":"18790_CR1","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","volume":"392","author":"KB Gordon","year":"2018","unstructured":"Gordon, K. B. et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet 392, 650\u2013661 (2018).","journal-title":"Lancet"},{"key":"18790_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.11.040","author":"K Reich","year":"2019","unstructured":"Reich, K. et al. Maintenance of clinical response and consistent safety profile with up to three years of continuous treatment with guselkumab: results from the VOYAGE 1 and VOYAGE 2 trials. J. Am. Acad. Dermatol. https:\/\/doi.org\/10.1016\/j.jaad.2019.11.040 (2019).","journal-title":"J. Am. Acad. Dermatol."},{"key":"18790_CR3","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1111\/jdv.15862","volume":"33","author":"A Blauvelt","year":"2019","unstructured":"Blauvelt, A. et al. Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials. J. Eur. Acad. Dermatol. Venereol. 33, 2305\u20132312 (2019).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"18790_CR4","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1001\/jamadermatol.2018.0183","volume":"154","author":"KJ Mason","year":"2018","unstructured":"Mason, K. J. et al. Comparison of drug discontinuation, effectiveness, and safety between clinical trial eligible and ineligible patients in BADBIR. JAMA Dermatol. 154, 581\u2013588 (2018).","journal-title":"JAMA Dermatol."},{"key":"18790_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15878","author":"M Masson Regnault","year":"2019","unstructured":"Masson Regnault, M. et al. Users of biologics in clinical practice: would they be eligible for phase III clinical studies? Cohort study in the French Psoriasis Registry PSOBIOTEQ. J. Eur. Acad. Dermatol. Venereol. https:\/\/doi.org\/10.1111\/jdv.15878 (2019).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"18790_CR6","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/bjd.17738","volume":"181","author":"A Mourad","year":"2019","unstructured":"Mourad, A., Straube, S., Armijo-Olivo, S. & Gniadecki, R. Factors predicting persistence of biologic drugs in psoriasis: a systematic review and meta-analysis. Br. J. Dermatol. 181, 450\u2013458 (2019).","journal-title":"Br. J. Dermatol."},{"key":"18790_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19701","author":"T Graier","year":"2020","unstructured":"Graier, T. et al. Biologic drug survival rates in the era of anti-Il-17 antibodies: a time period-adjusted registry analysis. Br. J. Dermatol. https:\/\/doi.org\/10.1111\/bjd.19701 (2020).","journal-title":"Br. J. Dermatol."},{"key":"18790_CR8","first-page":"320","volume":"179","author":"KA Papp","year":"2018","unstructured":"Papp, K. A. et al. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3. Br. J. Dermatol. 179, 320\u2013328 (2018).","journal-title":"Br. J. Dermatol."},{"key":"18790_CR9","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1111\/jdv.16521","volume":"34","author":"B Strober","year":"2020","unstructured":"Strober, B. et al. Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies. J. Eur. Acad. Dermatol. Venereol. 34, 2830\u20132838 (2020).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"18790_CR10","doi-asserted-by":"publisher","first-page":"319","DOI":"10.2165\/11310770-000000000-00000","volume":"10","author":"A Mazzotta","year":"2009","unstructured":"Mazzotta, A., Esposito, M., Costanzo, A. & Chimenti, S. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study. Am. J. Clin. Dermatol. 10, 319\u2013324 (2009).","journal-title":"Am. J. Clin. Dermatol."},{"key":"18790_CR11","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s40261-017-0603-3","volume":"38","author":"Y Hu","year":"2018","unstructured":"Hu, Y., Chen, Z., Gong, Y. & Shi, Y. A review of switching biologic agents in the treatment of moderate-to-severe plaque psoriasis. Clin. Drug Investig. 38, 191\u2013199 (2018).","journal-title":"Clin. Drug Investig."},{"key":"18790_CR12","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1007\/s13555-021-00573-1","volume":"11","author":"B Strober","year":"2021","unstructured":"Strober, B. et al. A Survey of Community dermatologists reveals the unnecessary impact of trial-and-error behavior on the psoriasis biologic treatment paradigm. Dermatol. Ther. (Heidelb) 11, 1851\u20131860 (2021).","journal-title":"Dermatol. Ther. (Heidelb)"},{"key":"18790_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jaad.2018.06.057","volume":"80","author":"SB Kaushik","year":"2019","unstructured":"Kaushik, S. B. & Lebwohl, M. G. Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents. J. Am. Acad. Dermatol. 80, 27\u201340 (2019).","journal-title":"J. Am. Acad. Dermatol."},{"key":"18790_CR14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jaad.2018.06.056","volume":"80","author":"SB Kaushik","year":"2019","unstructured":"Kaushik, S. B. & Lebwohl, M. G. Psoriasis: Which therapy for which patient: Focus on special populations and chronic infections. J. Am. Acad. Dermatol. 80, 43\u201353 (2019).","journal-title":"J. Am. Acad. Dermatol."},{"key":"18790_CR15","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s00403-019-01907-y","volume":"311","author":"I Gasslitter","year":"2019","unstructured":"Gasslitter, I. et al. Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study. Arch. Dermatol. Res. 311, 421\u2013424 (2019).","journal-title":"Arch. Dermatol. Res."},{"key":"18790_CR16","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1111\/bjd.19575","volume":"184","author":"R Reddy","year":"2021","unstructured":"Reddy, R., Pannu, S., Fiumara, K., Kahn, J. & Rosmarin, D. Efficacy of in-class interleukin-23 inhibitor switching: risankizumab following guselkumab failure in moderate-to-severe psoriasis treatment. Br. J. Dermatol. 184, 559\u2013561 (2021).","journal-title":"Br. J. Dermatol."},{"key":"18790_CR17","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1111\/bjd.12992","volume":"171","author":"M Inzinger","year":"2014","unstructured":"Inzinger, M. et al. Short- to intermediate-term follow-up in patients treated with the combination of 311-nm ultraviolet B phototherapy and biological agents. Br. J. Dermatol. 171, 915\u2013917 (2014).","journal-title":"Br. J. Dermatol."},{"key":"18790_CR18","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2340\/00015555-2214","volume":"96","author":"M Inzinger","year":"2016","unstructured":"Inzinger, M. et al. Survival and effectiveness of tumour necrosis factor-alpha inhibitors in the treatment of plaque psoriasis under daily life conditions: report from the psoriasis registry Austria. Acta Derm. Venereol. 96, 207\u2013212 (2016).","journal-title":"Acta Derm. Venereol."},{"key":"18790_CR19","first-page":"62","volume":"2","author":"T Graier","year":"2020","unstructured":"Graier, T., Weger, W., Sator, P. & Salmhofer, W. Effectiveness and clinical predictors of drug survival in psoriasis patients receiving apremilast: a registry analysis. J. Am. Acad. Dermatol. Int. 2, 62\u201375 (2020).","journal-title":"J. Am. Acad. Dermatol. Int."},{"key":"18790_CR20","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","volume":"394","author":"K Reich","year":"2019","unstructured":"Reich, K. et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet 394, 831\u2013839 (2019).","journal-title":"Lancet"},{"key":"18790_CR21","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt, A. et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator. J. Am. Acad. Dermatol. 76, 405\u2013417 (2017).","journal-title":"J. Am. Acad. Dermatol."},{"key":"18790_CR22","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1111\/1346-8138.14504","volume":"45","author":"M Ohtsuki","year":"2018","unstructured":"Ohtsuki, M. et al. Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study. J. Dermatol. 45, 1053\u20131062 (2018).","journal-title":"J. Dermatol."},{"key":"18790_CR23","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1080\/09546634.2021.1961998","volume":"33","author":"P Dapavo","year":"2021","unstructured":"Dapavo, P. et al. Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study. J. Dermatol. Treat. 33, 2352\u20132357 (2021).","journal-title":"J. Dermatol. Treat."},{"key":"18790_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09546634.2022.2036674","volume":"33","author":"M Megna","year":"2022","unstructured":"Megna, M., Potestio, L., Ruggiero, A., Camela, E. & Fabbrocini, G. Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study. J. Dermatol. Treat. 33, 1\u20135 (2022).","journal-title":"J. Dermatol. Treat."},{"key":"18790_CR25","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2022.2081655","author":"M Megna","year":"2022","unstructured":"Megna, M. et al. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study. J. Dermatol. Treat. https:\/\/doi.org\/10.1080\/09546634.2022.2081655 (2022).","journal-title":"J. Dermatol. Treat."},{"key":"18790_CR26","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","volume":"394","author":"K Reich","year":"2019","unstructured":"Reich, K. et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet 394, 576\u2013586 (2019).","journal-title":"Lancet"},{"key":"18790_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15524","author":"M Megna","year":"2022","unstructured":"Megna, M., Potestio, L., Ruggiero, A., Camela, E. & Fabbrocini, G. Risankizumab treatment in psoriasis patients who failed anti-IL17: A 52-week real-life study. Dermatol. Ther. https:\/\/doi.org\/10.1111\/dth.15524 (2022).","journal-title":"Dermatol. Ther."},{"key":"18790_CR28","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/ced.14979","volume":"47","author":"A Ruggiero","year":"2022","unstructured":"Ruggiero, A. et al. Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice. Clin. Exp. Dermatol. 47, 561\u2013567 (2022).","journal-title":"Clin. Exp. Dermatol."},{"key":"18790_CR29","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/1346-8138.14941","volume":"46","author":"M Ohtsuki","year":"2019","unstructured":"Ohtsuki, M. et al. Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: results from the SustaIMM phase 2\/3 trial. J. Dermatol. 46, 686\u2013694 (2019).","journal-title":"J. Dermatol."},{"key":"18790_CR30","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1111\/jdv.16187","volume":"34","author":"Y Poulin","year":"2020","unstructured":"Poulin, Y. et al. Efficacy of tildrakizumab by patient demographic and disease characteristics across a phase 2b and 2 phase 3 trials in patients with moderate-to-severe chronic plaque psoriasis. J. Eur. Acad. Dermatol. Venereol. 34, 1500\u20131509 (2020).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"18790_CR31","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","volume":"390","author":"K Reich","year":"2017","unstructured":"Reich, K. et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet 390, 276\u2013288 (2017).","journal-title":"Lancet"},{"key":"18790_CR32","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/bjd.18232","volume":"182","author":"K Reich","year":"2020","unstructured":"Reich, K. et al. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks. Br. J. Dermatol. 182, 605\u2013617 (2020).","journal-title":"Br. J. Dermatol."},{"key":"18790_CR33","first-page":"2","volume":"35","author":"G Caldarola","year":"2022","unstructured":"Caldarola, G. et al. Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study. Dermatol. Ther. 35, 2\u20137 (2022).","journal-title":"Dermatol. Ther."},{"key":"18790_CR34","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18361","author":"JM Norlin","year":"2019","unstructured":"Norlin, J. M., Nilsson, K., Persson, U. & Schmitt-Egenolf, M. Complete skin clearance and Psoriasis Area and Severity Index response rates in clinical practice: predictors, health-related quality of life improvements and implications for treatment goals. Br. J. Dermatol. https:\/\/doi.org\/10.1111\/bjd.18361 (2019).","journal-title":"Br. J. Dermatol."},{"key":"18790_CR35","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1080\/09546634.2017.1395794","volume":"29","author":"G Carretero","year":"2018","unstructured":"Carretero, G. et al. Redefining the therapeutic objective in psoriatic patients candidates for biological therapy. J. Dermatol. Treat. 29, 334\u2013346 (2018).","journal-title":"J. Dermatol. Treat."},{"key":"18790_CR36","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/bjd.15750","volume":"178","author":"RG Langley","year":"2018","unstructured":"Langley, R. G. et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br. J. Dermatol. 178, 114\u2013123 (2018).","journal-title":"Br. J. Dermatol."},{"key":"18790_CR37","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"K Reich","year":"2017","unstructured":"Reich, K. et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, p. J. Am. Acad. Dermatol. 76, 418\u2013431 (2017).","journal-title":"J. Am. Acad. Dermatol."},{"key":"18790_CR38","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1111\/jdv.13990","volume":"31","author":"AB Gottlieb","year":"2017","unstructured":"Gottlieb, A. B. et al. Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies. J. Eur. Acad. Dermatol. Venereol. 31, 679\u2013685 (2017).","journal-title":"J. Eur. Acad. Dermatol. Venereol."}],"updated-by":[{"DOI":"10.1038\/s41598-024-57807-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18790-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18790-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18790-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T08:11:54Z","timestamp":1711440714000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18790-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,5]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["18790"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-18790-9","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41598-024-57807-3","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,5]]},"assertion":[{"value":"7 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-024-57807-3","URL":"https:\/\/doi.org\/10.1038\/s41598-024-57807-3","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PW has received research grants, speaker and\/or consulting honoraria, and\/or travel refunds from AbbVie, Actavis,\u00a0Amgen GmbH, Almirall, Boehringer-Ingelheim, \u00a0BMS,\u00a0Celgene, Eli Lilly, Janssen, Leo Pharma, Novartis, Merck Sharp & Dohme,\u00a0Roche, Sandoz, Sanofi, Pfizer\u00a0and UCB. TG has received a travel grant from Novartis, speaker honoraria from Amgen\u00a0and Novartis, and consulting honoraria from Almirall. WS reports grants and personal fees from AbbVie, Almirall, Leo Pharma and Novartis. CJ served as PI (grant paid to institution), and\/or received speaker and\/or consulting honoraria, and\/or travel refunds from AbbVie, Almirall, Amgen, Eli Lilly, Janssen, Kyowa Kirin, LEO Pharma, Novartis, Pfizer, Recordati, Sandoz, Takeda UCB, and 4SC. WS reports grants and personal fees from Janssen, grants and personal fees from Amgen, grants and personal fees from Lilly, grants and personal fees from AbbVie, personal fees from Celgene, personal fees from Leo, personal fees from Novartis,  outside the submitted work. NH has received honoraria for advisory boards from Eli Lilly, Almirall, Novartis and Leo Pharma. KP has received speaker and consulting honoraria from: Abbvie, Eli Lilly, Janssen and Novartis. Travel refunds from: Abbvie, Almirall, Celgene, Eli Lilly, Janssen, Leo Pharma and Novartis. WW has received speaker and\/or consulting honoraria and\/or travel refunds from AbbVie, Amgen GmbHm Almirall, Celgene, Eli Lilly, Janssen, Leo Pharma, Novartis, Merck Sharp & Dohme, Sandoz and Pfizer. GR reports honoraria for training sessions or participation in advisory boards from Eli Lilly, Novartis, Janssen, UCB, Pelpharma, Abbvie, Leo Pharma. AM has received research grants, speaker and\/or consulting honoraria, and\/or travel refunds from AbbVie, Amgen GmbH, Almirall, Celgene, Eli Lilly, Janssen, Leo Pharma, Novartis, and Pfizer.\u00a0BS reports industry grants\/royalties from Abbott\/Abbvie, Almirall, Celgene, Eli-Lilly, Galderma, Novartis, Pfizer, Trevi Therapeutics, UCB and Janssen Cilag. PS has received research grants, speaker and\/or consulting honoraria, and\/or travel refunds from  Abbvie, Actelion, Amgen, Almirall, Janssen, Novartis,  Leo Pharma,  Pfizer,  MSD, Celgene,  Maruho, ALK, Galderma, Abbott,  UCB, Gilead, Lilly.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15078"}}